- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Neo Ivy Capital Management Trims Organon & Co. Stake
Hedge fund reduces holdings in pharmaceutical company by over 75%
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Neo Ivy Capital Management has reduced its stake in Organon & Co. (NYSE:OGN) by 76.9% in the third quarter, according to a recent SEC filing. The institutional investor now holds 30,038 shares of the company's stock, down from 130,136 shares previously.
Why it matters
Organon & Co. is a global pharmaceutical company focused on women's health, biosimilars, and established brands. The significant reduction in Neo Ivy Capital Management's position could signal concerns about the company's performance or outlook among some institutional investors.
The details
According to the SEC filing, Neo Ivy Capital Management sold 100,098 shares of Organon & Co. stock in the third quarter, leaving the firm with a remaining position of 30,038 shares valued at $321,000. The move comes as Organon & Co. has faced a challenging operating environment, with its stock price declining from a 52-week high of $16.08 to around $6.58 as of Monday's market open.
- Neo Ivy Capital Management filed its 13F report for the third quarter of 2026 on March 9, 2026.
- Organon & Co. shares opened at $6.58 on Monday, March 9, 2026.
The players
Neo Ivy Capital Management
A hedge fund that has reduced its stake in Organon & Co. by over 75% in the third quarter of 2026.
Organon & Co.
A global pharmaceutical company focused on women's health, biosimilars, and established brands that has seen its stock price decline in recent months.
The takeaway
The significant reduction in Neo Ivy Capital Management's position in Organon & Co. could signal broader concerns about the pharmaceutical company's performance and outlook among some institutional investors. This development bears watching as Organon navigates the challenges facing its business.
